Pharma's Almanac TV
PA TV
Your Name
Your Email
Manage Account
Sign Out
Sign In
Register
Follow the Journey
Companies On The Road
Arcadis DPS Group
C2 Pharma
CAI
EcoLab
Environmental Systems Corporation
Federal Equipment Company
Globyz Biopharma Services
Grifols
Integrity
Nu-Tek BioSciences
PHARMALEX
Waters Corporation
Follow the Journey
Companies On The Road
ABS
aCGT Vector
Alconox Inc.
Andelyn Biosciences
Arranta Bio
Avid Bioservices
BDD
BIOVECTRA
DPS Group
Dynamk Capital
Environmental Systems Corporation
Federal Equipment Company
Genesis AEC
Globyz Biopharma Services
Grifols Partnership
IDT Biologika
Inceptor Bio
IPS-Integrated Project Services
Kineticos Life Sciences
MilliporeSigma
Montana BioScience Alliance
Olon
Rentschler Biopharma
SanaClis
Scorpion Biological Services
Secant Group
Tapemark
VITRONIC
Follow the Journey
Companies On The Road
AES Clean Technology
Altis Biosystems
Arranta Bio
Avara Pharmaceutical Services
Avid Bioservices
BioVectra
Centaur BPS
Dynamk Capital
ECRI
Evolve Biologics
Federal Equipment Company
Globyz
Inceptor Bio
IPS-Integrated Project Services
Olon
Pii
Polpharma Biologics
PPD
RoosterBio
SanaClis
Sanofi AIS
SGD Pharma
SPI Pharma
TriRx Pharmaceutical Services
Yourway
Dashboard
Topics
Products
ADC
API - Small Molecule
Biologics
Biopharmaceuticals
Biosimilars
Cell and Gene Therapy
DNA
Drug Product
Drug Substance
Equipment
Generics
Immunotherapy
Injectables
Monoclonal Antibody
Novel Therapeutics
Oral Solid Dosage
Orphan Drugs
Parenterals
Stem Cells
Vaccine
Services
Big Data
Bioprocessing
Clinical Trials
Continuous Manufacturing
Diagnostics
Drug Delivery
Drug Development
Drug Discovery
Facility
Formulation
Innovation
Oncology
Patient Adherence
Patient Centric
Preclinical
Process Development
Quality
Regulatory
Research
Serialization
Segment
Biomanufacturing
Biotechnology
CDMO
Consulting
CRO
Engineering
Equipment
Excipients
Healthcare
Intermediates
Logistics
Manufacturing
Packaging
Supply Chain
Business
Agreement
Appointment
Business
Capacity Expansion
Collaboration
Growth
Investment
Licensing
M&A
Market Expansion
Market Intelligence
Market Prediction
New Facility
Strategic Partnership
Magazine
Archive
Reports
Nice Insight Reports
2022 Sterile
2023 Cell & Gene Therapy
2023 mAb and Recombinant Protein
2024 API
2024 OSD
2024 ADC
2024 mRNA
2024 Mammalian Cell Culture
2024 Microbial Cell Culture
2024 Plasmids
2024 Gene Therapy
2024 Cell Therapy
2024 Sterile
Community
Company A to Z
Follow the Journey
Companies On The Road
Follow The Artist
Follow the Journey
Companies On The Road
More+
Staffing
Media Kit
Novartis (3)
74 Articles Available
3
4
Can't find what you're looking for? Try our
advanced search
.
Drug Development
Novartis announces FDA approval of Gilenya® as the first disease-modifying therapy for pediatric relapsing multiple sclerosis
PR-M05-18-NI-060
Clinical Trials
Novartis launches FocalView app, providing opportunity for patients to participate in ophthalmology clinical trials from home
PR-M04-18-NI-100
Drug Development
Novartis drug Afinitor DISPERZ® receives FDA approval to treat TSC-associated partial-onset seizures
PR-M04-18-NI-49
Acquisition
GSK to Take Over Full Ownership of Consumer Healthcare JV with Novartis
PAO-M04-18-NI-008
Clinical Data
Clinical Study Data for New MS Drug Looks Promising
PR-M03-18-NI-101
Clinical Data
Phase III data in The Lancet show Novartis siponimod significantly improved outcomes in patients with secondary progressive MS
PR-M03-18-NI-095
FDA
Novartis drug Tasigna® approved by FDA to treat children with rare form of leukemia
PR-M03-18-NI-094
Immunotherapy
Harvard Bioengineers' Biomaterial-Based Cancer Immunotherapies to be Developed by Novartis
PR-M03-18-NI-082
Cannibis
Medical Marijuana Moves to the Big Time
PAO-M03-18-NI-019
Biologics
Next Generation Biologics, Janssen's Tremfya, Eli Lilly's Taltz, and Novartis' Cosentyx, Raising the Bar in Psoriasis Management
PR-M03-18-NI-040
Digital
Novartis in Collaboration to Develop Software Applications
PAO-M03-18-NI-006
Clinical Data
Novartis new data show Cosentyx® improved quality of life over 5 years in two thirds of patients with moderate to severe plaque psoriasis
PR-M02-18-NI-88
FDA
Label Update Approved for Novartis’ Cosentyx
PAO-M02-18-NI-014
FDA Approval
Novartis receives FDA approval for Cosentyx® label update to include moderate to severe scalp psoriasis
PR-M02-18-NI-046
Clinical Trials
Novartis Announces NEJM Publication Of Updated Analysis From ELIANA Trial Showing Longer-Term Durable Remissions With Kymriah™ In Children, Young Adults With r/r ALL
PR-M02-18-NI-019
Biosimilars
Novartis Makes More Biosimilar Moves
PAO-M01-18-NI-047
Clinical Trial
Amgen and Novartis Reach an Important Milestone
PAO-M01-18-NI-041
Drug Development
Promacta Gets Breakthrough Therapy Designation
PAO-M01-18-NI-012
Gene Editing
More Gene Editing Technology Being Developed by Novartis
PAO-M11-17-NI-043
Drug Development
Amgen and Novartis Expand Collaboration to Prevent Alzheimer’s
PAO-M11-17-NI-009
Acquistion
Novartis Plans Acquisition of Advanced Accelerator Applications for $3.9 Billion
PAO-M10-17-NI-045
FDA Approval
Novartis Receives First Ever FDA Approval For A CAR-T Cell Therapy, Kymriah(TM) (CTL019)
PR-M08-17-NI-010
Innovation
First-in-Class Cancer Treatment Enters New Era
PAO-M09-17-NI-008
Partnership
Magnetic Bead Technology Activates Novartis’ CAR-T Therapy
PAO-M09-17-NI-007
«
3
4
»
.svg)
